On Oct 24, major Wall Street analysts update their ratings for $Boston Scientific (BSX.US)$, with price targets ranging from $97 to $100.
Morgan Stanley analyst Patrick Wood maintains with a buy rating, and adjusts the target price from $92 to $100.
BofA Securities analyst Travis Steed maintains with a buy rating, and maintains the target price at $100.
Citi analyst Joanne Wuensch maintains with a buy rating.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $87 to $98.
Jefferies analyst Matthew Taylor maintains with a buy rating, and adjusts the target price from $90 to $100.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific has delivered a quarter that exceeded expectations on all fronts, despite already high anticipations. The pause in the AVANT GUARD clinical trial studying Farapulse in persistent drug-naive patients has placed some pressure on the company's shares. It is important to note that the current pause pertains to a patient segment not currently under treatment, and there are aspects that require evaluation. The expectation is for enrollment to recommence shortly.
Boston Scientific is perceived as having 'best in medtech growth,' with increased confidence in the company's growth projection and the sustainability of its double-digit revenue expansion. It is noted that Boston Scientific possesses one of the most comprehensive pipelines in the medtech sector and that much of its revenue growth contributes positively to profit margins.
The recent pullback in Boston Scientific shares is seen as offering a 'compelling' entry point. This assessment comes despite the AVANT Guard trial setback, which is noteworthy for not being associated with a mortality event or instigated by the FDA. Furthermore, the sustained global momentum of Farapulse is anticipated to continue over the medium term.
Boston Scientific's third-quarter revenue and EPS surpassed expectations, with U.S. Farapulse sales notably doubling over the previous quarter, a performance that outpaced predictions. The company also increased its revenue and EPS guidance for 2024 and offered preliminary insights into its 2025 projections.
Expectations were notably high for Boston Scientific leading into the Q3 results, which ultimately met the anticipation. Despite the positive outcome, there was unexpected commentary about a temporary halt in the AVANT GUARD trial, which is investigating pulsed field ablation as a primary treatment for persistent atrial fibrillation. While the pause is due to some unanticipated observations that are not life-threatening, it has caused the shares to trade down even after a commendable report. It is believed that the market reaction is somewhat myopic, given that the enrollment is anticipated to continue shortly. Nonetheless, there is an understanding of the concerns regarding any issues with a crucial product that has the potential to expand the total addressable market.
Here are the latest investment ratings and price targets for $Boston Scientific (BSX.US)$ from 12 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月24日，多家华尔街大行更新了$波士顿科学 (BSX.US)$的评级，目标价介于97美元至100美元。
摩根士丹利分析师Patrick Wood维持买入评级，并将目标价从92美元上调至100美元。
美银证券分析师Travis Steed维持买入评级，维持目标价100美元。
花旗分析师Joanne Wuensch维持买入评级。
富国集团分析师Larry Biegelsen维持买入评级，并将目标价从87美元上调至98美元。
富瑞集团分析师Matthew Taylor维持买入评级，并将目标价从90美元上调至100美元。
此外，综合报道，$波士顿科学 (BSX.US)$近期主要分析师观点如下：
波士顿科学在各方面均超出预期的一季度表现优异，尽管预期已经很高。在研究持续未接受药物治疗的患者中进行的AVANt GUARD临床试验暂停，给公司股票带来了一定压力。重要的是要注意，当前的暂停涉及目前未接受治疗的患者群，还有需要评估的方面。预计很快将重新开始招募。
波士顿科学被视为具有“医疗科技增长最佳”，对公司增长预期和其两位数营业收入扩张的可持续性增加了信心。值得注意的是，波士顿科学拥有医疗科技领域最全面的产品线之一，其大部分营业收入增长对利润率有积极贡献。
波士顿科学股价最近回调被视为提供了一个“引人注目”的入场点。尽管AVANt Guard试验出现了挫折，但并未与死亡事件有关，也不是由FDA发起的。此外，Farapulse在全球的持续势头预计将在中期继续。
波士顿科学第三季度营业收入和每股收益超出预期，美国Farapulse销售额显著较上一季度翻了一番，表现超出预测。公司还提高了2024年的营业收入和每股收益预测，并提供了对2025年预测的初步见解。
波士顿科学在第三季度业绩发布前市场期望高涨，最终符合预期。尽管结果积极，却有意想不到的评论称AVANt GUARD试验出现暂停，该试验是研究脉冲场消融作为持续性心房颤动的一线治疗。尽管暂停是由于一些非预期观察并不危及生命，但即使在一份值得称赞的报告后，它导致股价下跌。市场反应被认为有些短视，因为预计招募很快将继续。尽管如此，对于拥有扩大总可寻址市场潜力的关键产品出现任何问题的担忧是可以理解的。
以下为今日12位分析师对$波士顿科学 (BSX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
